FDA approves Glenmark’s Vfend generic

MUMBAI, India — Glenmark pharmaceuticals announced recently that the Food and Drug Administration had approved its generic of Pfizer’s Vfend (voriconazole) tablets. The drug, which is indicated to treat fundal infections, is available in 50- and 200-mg dosage strengths.

Vfend saw U.S. sales of about $9.14 million in the 12 months ended July 2015, according to IMS Health data.